Back to Search

A Phase 1/2a, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-3312 Based Combination Therapies in Adult Patients With Advanced Solid Tumors

  • Protocol Number: 202103029
  • Principal Investigator: Morgensztern, Daniel
  • Cancer Types: Early Phase, Lung

For more information on this trial, contact us here:


Brief Summary

Protocol Interventions